The renin-angiotensin system in essential hypertension: Associations with cardiovascular risk

Blood Pressure

Volumn 8, Issue 2, 1999, Pages 70-78

  Allikmets, Kristina ^a   Parik, Triin ^a   Viigimaa, Margus ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

Cardiovascular risk; Essential hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DRUG TARGETING; ESSENTIAL HYPERTENSION; GENETIC SUSCEPTIBILITY; HUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM BALANCE; SYMPATHETIC TONE; TREATMENT PLANNING;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0032774752     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599438239     Document Type: Review

References (111)

1. Kannel WB. Hypertension as a risk factor for cardiac events - epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993; 21 (Suppl 2): S27-37.
2. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens 1994; 12 (Suppl 10): S5-14.
3. Collins R, Peto S, MacMahon S, Herbert P, Fiebach N, Eberlein K, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
4. Genest J Jr, Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1995; 76: 8A-20A.
5. Kannel WB. Coronary risk factors: an overview. In: Willerson JT, Cohn JS (eds). Cardiovascular medicine. New York: Churchill Livingstone, 1995: 1809-28.
6. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. New Engl J Med 1972; 286: 441-9.
7. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. New Engl J Med 1991; 324: 1098-104.
8. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10: 1-8.
9. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol 1997; 79: 9-11.
10. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79: 12-6.
11. Lind L, Reneland R, Andersson PE, Haenni A, Lithell H. Insulin resistance in essential hypertension is related to plasma renin activity. J Hum Hypertens 1998; 12: 379-82.
12. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 1997; 15: 1579-92.
13. Harrap SB. Cardiovascular disease and genetics of the renin-angiotensin system. Heart 1996; 76 (Suppl 3): 13-7.
14. Cockcroft J, O'Kane KP, Webb DJ. Tissue angiotensin generation and regulation of vascular tone. Pharmacol Ther 1995; 65: 193-213.
15. Morgan T, Brunner HR. The renin-angiotensin system and the heart: beyond 2000. Heart 1996; 76: 98-103.
16. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
17. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
18. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
19. Hansson L, Hedner T, Lindholm L, Niklason A, Luomanmaki K, Niskanen L, et al. The Captopril Prevention Project (CAPPP) in hypertension - baseline data and current status. Blood Press 1997; 6: 365-7.
20. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
21. Tigerstedt R, Bergman PG. Niere und Kreislauf. Skandinavisches Archiv für Physiologie 1898; 8: 223-71.
22. Hall J, Guyton A. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM (eds). Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1990: 1105-25.
23. Paran E, Nemenoff RA, Schrier RW. Role of the renin-angiotensin system in essential hypertension. Curr Opin Nephrol Hypertens 1995; 4: 295-9.
24. Harris PJ, Young JA. Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Arch 1977; 367: 295-7.
25. Nahmias AJ, Strosberg AD. The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function. Trends Pharmacol Sci 1995; 16: 223-5.
26. Weinberger MH, Wade MB, Aoi W, Usa T, Dentino M, Luft F, Grim CE. An extrarenal source of "renin-like" activity in anephric man. Circ Res 1977; 40 (Suppl 1): 1-4.
27. Dzau VJ, Gibbons GH, Cooke JP, Omoigui N. Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives. Circulation 1993; 87: 705-19.
28. Lindpaintner K, Ganten D. The cardiac renin angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68: 905-21.
29. Naruse M, Takii Y, Inagami T. Renin exists in high concentration in the adrenal gland of the rat. Biomed Res 1981; 2: 583-4.
30. Ganten D, Hermann K, Bayer C, Unger T, Lang RE. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 1982; 222: 869-71.
31. von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994; 89: 458-70.
32. Danser AHJ, Schalekamp MADH. Is there an internal cardiac renin angiotensin system? Heart 1996; 76 (Suppl 3): 28-32.
33. Stock P, Liefeldt L, Paul M, Ganten D. Local renin-angiotensin systems in cardiovascular tissues: localization and functional role. Cardiology 1995; 86 (Suppl 1): 2-8.
34. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811-9.
35. Nussberger J, Brunner HR. Measurement of angiotensins in plasma. In: Nicholls MG, Robertson JIS (eds). The renin-angiotensin system London: Gower Medical Publishing, 1993: 15.1-15.13.
36. Osmond DH, Ross LJ, Scaiff KD. Increased renin activity after cold storage of human plasma. Can J Physiol Pharmacol 1973; 51: 705-8.
37. Brandenberger G, Follenius M, Goichot B, Saini J, Spiegel K, Erhart J, et al. Twenty-four-hour profiles of plasma renin activity in relation to sleep-wake cycle. J Hypertens 1994; 12: 277-83.
38. Bauer JH. Age-related changes in the renin-aldosterone system. Drugs Aging 1993; 3: 238-45.
39. Nicholls MG, Robertson JIS. Changes in renin secretion. In: Nicholls MG, Robertson JIS (eds). The renin-angiotensin system. London: Gower Medical Publishing, 1993: 74.1-74.12.
40. Doig JK, Lees KR, Reid JI. The effect of drugs on the renin-angiotensin system in man. In: Nicholls MG, Robertson JIS (eds). The renin-angiotensin system. London: Gower Medical Publishing, 1993: 80.1-80.19.
41. Brown JJ, Davies DL, Lever AF, Robertson JIS. Influence of sodium loading and sodium depletion on plasma renin activity in man. Lancet 1963; ii: 278-9.
42. Thurston H, Bing RF, Pohl JEF, Swales JD. Renin subgroups in essential hypertension; an analysis and critique. Q J Med 1978; 47: 325-37.
43. Lucas CP, Holtzwarth GJ, Ocoback RW, Stern MP, Haskell WL, Sozen T, et al. Disturbed relationship of plasma renin to blood pressure in hypertension. Lancet 1974; ii: 1337.
44. Thomas GW, Ledingham JGG, Beilin LJ, Stott AN, Yeates KM. Reduced renin activity in essential hypertension: a reappraisal. Kidney Int 1977; 13: 513-8.
45. Padfield PL, Brown JJ, Lever AF, Schalekamp LA, Beevers DG, Davies DL, et al. Is low renin hypertension a stage in the development of essential hypertension or a diagnostic entity? Lancet 1975; I: 548-50.
46. Schmieder RE, Weihprecht H, Schobel H, et al. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94: 1304-9.
47. Laragh JH. Nephron heterogeneity: clue to the pathogenesis of essential hypertension and effectiveness of angiotensin-converting enzyme inhibitor treatment. Am J Med 1989; 87 (Suppl 6B): 2S-14S.
48. Swales JD. The renin-angiotensin system in essential hypertension. In: Nicholls MG, Robertson JIS (eds). The renin-angiotensin system. London: Gower Medical Publishing, 1993: 62.1-62.12.
49. Sommers SC, Melamed J. Renal pathology of essential hypertension. Am J Hypertens 1990; 3: 583-7.
50. De Leeuw PW, Birkenhäger WH. Renal involvement in essential hypertension and treatment effects. Netherlands J Med 1995; 47: 199-204.
51. Ritz E, Fliser D, Siebels M. Pathophysiology of hypertensive renal damage. Am J Hypertens 1993; 6: 241S-4S.
52. Weinberger MH, Yu PL, Perkins BJ. Renin in hypertension: further evidence for a vasculotoxic role. Clin Res 1973; 21: 458.
53. Christlieb AR, Gleason RE, Hickler RB, Lauler DP. Renin: a risk factor for cardiovascular disease? Ann Intern Med 1974; 81: 7-10.
54. Mroczec WJ, Finnerty FA, Catt KJ. Lack of association between plasma renin and history of heart attack and stroke in patients with essential hypertension. Lancet 1973; ii: 464-9.
55. Abe K, Irokawa N, Ioyagi H, Memezawa H, Yasujima M, Otsuka Y, et al. Circulating renin in essential hypertension: an evaluation of its significance in the Japanese population. Am Heart Journal 1975; 89: 723-30.
56. Russel GI, Bing RF, Thurston H, Swales J. Plasma renin in hypertensive patients: significance in relation to clinical and other bio chemical features. Q J Med 1980; 49: 385-9.
57. Meade TW, Imeson JD, Gordon D, Peart WS. The epidemiology of plasma renin. Clin Sci 1983; 64: 273-80.
58. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. New Engl J Med 1991; 324: 1098-104.
59. Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension 1995; 25: 1144-52.
60. MacGregor GA. Low urinary sodium and myocardial infarction. Hypertension 1996; 27: 156.
61. Alderman MH. Plasma renin activity and coronary heart disease: are they related? Curr Opin Nephrol Hypertens 1995; 4: 201-3.
62. Laragh JH, Sealey JE. Abnormal sodium metabolism and plasma renin activity (renal renin secretion) and the vasoconstriction volume hypothesis: implications for pathogenesis and treatment of hypertension and its consequences (heart attack, stroke). Clin Chem 1991; 37: 1820-7.
63. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med 1979; 301: 1273-6.
64. Haab F, Duclos JM, Guyenne T, Plouin PF, Corvol P. Renin secreting tumors: diagnosis, conservative surgical approach and long-term results. J Urol 1995; 153: 1781-4.
65. Ruggenenti P, Remuzzi G. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Am J Kidney Dis 1996; 27: 459-75.
66. Winternitz MC, Mylon E, Waters LL, Katzenstein R. Studies on the relation of the kidney to cardiovascular disease. Yale J Biol Med 1940; 12: 623-82.
67. Gavras H, Brown JJ, Lever AF, Macadam RF, Robertson JIS. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971; 2: 19-22.
68. Ledingham JM. The vascular fault in hypertension: Byrom's work revisited. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1990: 33-48.
69. Gavras H, Kremer D, Brown JJ, Gray B, Lever AF, Macadam RF, Medina A, Morton JJ, Robertson JIS. Andiotensin and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbit and man. Am Heart J 1975; 89: 321-2.
70. Powell JS, Clozel J-P, Müller RKM. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
71. Hafizi S, Chester AH, Allen SP, Morgan K, Yacoub MH. Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade. Coron Artery Dis 1998; 9: 167-75.
72. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-503.
73. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
74. Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am J Hypertens 1992; 5: 276-80.
75. Schelling P, Fisher A, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3-15.
76. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implication of echocardiographically detected left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322: 1561-6.
77. Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998; 63: 1-11.
78. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994; 107: 71-84.
79. Fuhrman B, Judith O, Keidar S, Ben-Yaish L, Kaplan M, Aviram M. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radical Biol Med 1997; 23: 34-46.
80. Harrap SB. Cardiovascular disease and genetics of the renin-angiotensin system. Heart 1996; 76 (Suppl 3): 13-7.
81. Kreutz R, Hubner N, Ganten D, Lindpaintner K. Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension. Circulation 1995; 92: 2381-4.
82. Cambien F, Poirier O, Lecerf L, Evans A, Cambon JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
83. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90: 2622-8.
84. Corvol P, Soubrier F, Jeunemaitre X. Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension. Pathol Biol (Paris) 1997; 45: 229-39.
85. Sato N, Katsuya T, Rakugi H, Takami S, Nakata Y, Miki T, et al. Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hypertens 1997; 30: 321-5.
86. Katsuya T, Koike G, Yee TW, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995; 345: 1600-3.
87. Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 1992; 19: S30-88.
88. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80: 9J-14J.
89. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 1996; 94: 690-7.
90. Palatini P, Julius S. Heart reate and the cardiovascular risk. J Hypertens 1997; 15: 1-15.
91. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (Suppl F): F14-8.
92. Lind L, Lithell H, Wide L, Ljunghall S. Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension. J Hum Hypertens 1992; 6: 27-9.
93. Allikmets K, Parik T, Teesalu R. Association between plasma renin activity and metabolic cardiovascular risk factors in essential hypertension. J Intern Med 1996; 239: 49-55.
94. Pan WH, Chou J, Yeh SH, Tu CA. Correlates of blood pressure differ in high ana low plasma renin groups. J Hum Hypertens 1992; 6: 199-204.
95. Townsend RR, Zhao H. Plasma renin activity and insulin sensitivity in normotensive subjects. Am J Hypertens 1994; 7: 894-8.
96. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Am J Med 1981; 70: 1195-202.
97. Chien S. Blood rheology in myocardial infarction and hypertension. Biorheology 1986; 23: 633-53.
98. Allikmets K, Parik T, Teesalu R. Fibrinogen and the albumin-globulin ratio in essential hypertension: relations to plasma renin activity. J Hum Hypertens 1996; 10: 105-9.
99. Beamer N, Coull BM, Sexton G, de Garmo P, Knox R, Seaman G. Fibrinogen and the albumin-globulin ratio in recurrent stroke. Stroke 1993; 24: 1133-9.
100. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and a review of the literature. Ann Intern Med 1993; 118: 956-63.
101. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk 1995; 2: 197-205.
102. Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
103. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Cin Invest 1995; 95: 995-1001.
104. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79: 12-6.
105. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
106. Vaughan DE, Rouleau J-L, Pfeffer MA. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995; 16 (Suppl K): 31-6.
107. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1977; 77: 522-5.
108. Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
109. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1993; 23: 195-9.
110. Allikmets K, Parik T, Teesalu R. Efficacy and renal effects of isradipine in essential hypertension: association with renin system activity. Angiology 1997; 48: 977-84.
111. Mimran A, Ribstein J, DuCailar G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension 1994; 23: 1018-21.